Presigen Co., Ltd. (PGEN) 2026 First Quarter Monetary Report Might 13, 2026 4:30pm EDT
Taking part corporations
Stevenharasym – Vice President and Head of Investor Relations
Helen Sabzevari – President, CEO, Director
Phil Tennant – Chief Industrial Officer
Harry Thomasian – Chief Monetary Officer
Convention name contributors
Jason Butler – Residents JMP Securities, LLC, Analysis Division
brian chen
Swayampakula Ramakanth – HC Wainwright & Co, LLC, Analysis Division
presentation
operator
Hi there everybody. Welcome to the Precigen Q1 2026 Monetary Outcomes and Enterprise Updates Convention Name.
[Operator Instructions] This name was recorded on Wednesday, Might 13, 2026.
I’d now like at hand over the assembly to Mr. Stephen Harasim. Please, please.
Stephen Harasim
Vice President and Head of Investor Relations
Pricey Operators, Thanks to everybody who participated in our Q1 2026 replace name right now.
Becoming a member of us right now is our President and CEO, Dr. Helen Sabzevari. Phil Tennant, our Chief Industrial Officer. Mr. Harry Thomasian, CFO of the Firm. And our COO Mr. Rahul Shah.
Earlier than I start my ready remarks, I want to remind everybody that I will probably be guaranteeing forward-looking statements on this convention name. These statements are based mostly on our present expectations and beliefs. We encourage you to evaluate the slides on this presentation and our SEC filings. These contain dangers and uncertainties that would trigger precise outcomes to vary materially from these in right now’s forward-looking statements.
I’ll now flip the decision over to Dr. Sabzevari.
Helen Sabzevari
Consultant Director, President, CEO and Director
Thanks, Steve, and everybody who joined us on the primary quarter replace name.
The approval of PAPZIMEOS in August 2025 gives a brand new first-line commonplace of look after adults with RRP. In simply 9 months, now we have seen important progress with the launch of the primary commercially obtainable remedy.
